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Abstract
Background: Andrographolide is the major bioactive compound isolated from Andrographis paniculata, a native South
Asian herb used medicinally for its anti-inflammatory properties. In this study, we aimed to assess andrographolide’s
potential utility as an anti-neuroinflammatory therapeutic.
Methods: The effects of andrographolide on lipopolysaccharide (LPS)-induced chemokine up-regulation both in mouse
cortex and in cultured primary astrocytes were measured, including cytokine profiling, gene expression, and, in cultured
astrocytes, activation of putative signaling regulators.
Results: Orally administered andrographolide significantly attenuated mouse cortical chemokine levels from the C-C and
C-X-C subfamilies. Similarly, andrographolide abrogated a range of LPS-induced chemokines as well as tumor
necrosis factor (TNF)-α in astrocytes. In astrocytes, the inhibitory actions of andrographolide on chemokine and
TNF-α up-regulation appeared to be mediated by nuclear factor-κB (NF-κB) or c-Jun N-terminal kinase (JNK) activation.
Conclusions: These results suggest that andrographolide may be useful as a therapeutic for neuroinflammatory
diseases, especially those characterized by chemokine dysregulation.
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Background
Chemokines are small (8–12 kDa), chemotactic proteins
with multiple functions. In the central nervous system
(CNS), chemokines mediate innate and adaptive immune
responses, signaling for leukocyte recruitment as well as
glial cell activation during neuroinflammation [1]. Further-
more, they are known to play important roles in interneur-
onal communication, neuronal progenitor cell migration,
and oligodendrocyte maturation [2–4]. Chemokines are di-
vided into four subfamilies, namely C-C, C-X-C, C-X3-C,
and C based on the relative positions of conserved cysteine
residues in the N terminus [5]. Among the subfamilies, the
C-C and C-X-C chemokines comprise the two largest
groups [5]. In response to interleukin (IL)-1β or tumor ne-
crosis factor (TNF)-α released during the acute phases of
pathogen invasion or tissue injury, multiple cytokines/che-
mokines are up-regulated, then secreted by cells (primarily
microglia and astrocytes) of the brain parenchyma [6, 7].
While cytokines/chemokines help clear harmful stimuli by
initiating inflammatory responses and recruiting peripheral
immune cells, dysregulation of chemokines has been impli-
cated in various neurological diseases characterized by
neuroinflammation, including neurodegenerative demen-
tias such as Alzheimer’s disease, multiple sclerosis, trau-
matic brain injury, and specific types of meningitis [8–11].
Therefore, there is an unmet need for safe and potent anti-
neuroinflammatory therapeutics.
Andrographolide is a bioactive labdane diterpenoid de-
rived from the herbaceous Andrographis paniculata, which
* Correspondence: mitchell.lai@dementia-research.org
1Department of Pharmacology, Yong Loo Lin School of Medicine, National
University of Singapore, 16 Medical Drive, Kent Ridge 117600, Singapore
Full list of author information is available at the end of the article
© 2016 Wong et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wong et al. Journal of Neuroinflammation  (2016) 13:34 
DOI 10.1186/s12974-016-0498-6
has been traditionally used in Asia to treat a variety of ail-
ments, including fever, cough, tuberculosis, snake bites, and
respiratory or urinary tract infections [12, 13]. Androgra-
pholide has been found to have anti-cancer, anti-bacterial,
anti-inflammatory, and anti-oxidative effects in target or-
gans such as liver, lung, and bladder [14–18], where the
molecules are purported to permeate cells via passive diffu-
sion [19], as a andrographolide-specific receptor has not
been described as yet. The extracts of A. paniculata, whose
pharmacological efficacy is attributed mainly to androgra-
pholide [13], have been used in clinical trials for various in-
flammatory conditions [20, 21]. In contrast, there are few
studies which assessed the anti-neuroinflammatory effects
of andrographolide. We and others have previously re-
ported anti-inflammatory and neuroprotective effects of
andrographolide which seem to be mediated via regulation
of microglia as well as astrocytes [22, 23]. We have also
shown that andrographolide attenuated IL-1β-stimulated
up-regulation of the C-C motif ligand 5 (CCL5) chemokine
via nuclear factor-κB (NF-κB) inhibition in vitro [24]. How-
ever, it is unclear whether this effect applies to other che-
mokines, whether it is effective in animals using more
disease-relevant models such as bacterial lipopolysaccharide
(LPS) endotoxin injection or whether it may involve other
signaling molecules besides NF-κB. For example, c-Jun N-
terminal kinase (JNK)-mediated signaling is known to be
involved in neuroinflammation, and andrographolide has
been reported to activate JNK in various cell types [25–28],
but it is not clear whether JNK regulation mediates the ef-
fects of andrographolide on neuroinflammation. Further-
more, there is increasing recognition that astrocytes play an
integral role in regulating neuroinflammatory responses but
are less well studied compared to microglia [29–31]. In this
study, we first examined the effects of andrographolide
treatment on the cortical chemokine levels of mice sub-
jected to LPS injections. Next, we studied changes in ex-
pression of a range of chemokines and activation of
signaling molecules in LPS/andrographolide-treated rat pri-
mary astrocytes.
Methods
Reagents, rodent treatment, and brain tissue processing
Andrographolide (>98 % purity, Fig. 1a), LPS from Sal-
monella enterica, as well as other reagent grade chemi-
cals were purchased from Sigma-Aldrich Ltd. (St. Louis,
MO, USA) unless otherwise specified. Animals were ob-
tained from the Centre for Animal Resources, National
University of Singapore (NUS), and housed in ventilated
Fig. 1 Oral andrographolide inhibited LPS-mediated C-C and C-X-C chemokines in mouse cortex. a Structure of andrographolide: 3-[2-[decahydro-6-
hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-napthalenyl]ethylidene]dihydro-4-hydroxy-2(3H)-furanone (CAS no. 5508-58-7). b Mouse LPS
treatment regimen with three intraperitoneal LPS injections (3 mg/kg per injection) over 24 h, with andrographolide (25 or 50 mg/kg) administered by
oral gavage 1 h after each LPS injection, and animals sacrificed 5 h after the last injection for collection of brain. c Bar graphs showing mean ± SEM
concentrations of various chemokines (in pg/mg total brain protein) in the cortex of control mice (injections with PBS and gavage with PEG vehicle);
LPS only (LPS injections and gavage with vehicle); LPS + 25 mg/kg andrographolide; and LPS + 50 mg/kg andrographolide (N = 7–9 animals per group).
*p < 0.05; **p < 0.01; ***p < 0.001. n.s. not significant (p > 0.05) for multiple pair-wise comparisons (one-way ANOVA with Bonferroni’s post hoc tests)
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cages in the NUS vivarium on a 12-h light/12-h dark
cycle, with ad libitum access to water and standard
chow. The study has been approved by the Institutional
Animal Care and Use Committee at NUS (S13-5925,
S13-6210 and NUS127/08) and followed the ARRIVE
guidelines of the National Centre for the Replacement
Refinement and Reduction of Animals in Research. ICR
mice (male, 20 g ± 3 g) were randomly selected, then
subjected to three intraperitoneal (i.p.) injection of LPS
(3 mg/kg) over 24 h, together with oral gavage of ve-
hicle (polyethylene glycol, PEG, 100 μL) or androgra-
pholide (25 or 50 mg/kg) 1 h after each injection, based
on slight modifications of a previously published regimen
[32] (see Fig. 1b). Control mice were injected i.p. with
phosphate-buffered saline and orally administered PEG on
the same regimen. The mice were sacrificed 4 h after the
last andrographolide gavage, and the brains were dissected
free of the meninges and cerebellum, followed by
homogenization in ice-cold buffer (50 mM Tris-HCl,
120 mM NaCl, 5 mM KCl, 2 μg/mL pepstatin A, sup-
plemented with Complete ULTRA™ protease inhibitor
tablets and PhosSTOP™ phosphatase inhibitor from Roche
Life Science, Penzberg, Germany) using a Ultra-Turrax®
handheld homogenizer (IKA-Werke, Staufen im Breisgau,
Germany). Cortical homogenates were agitated on ice in
an ultrasonicator for 40 min, then centrifuged at 6000×g
for 20 min at 4 °C. The resultant supernatant was ali-
quoted and stored at −80 °C. Primary astrocyte cultures
for in vitro assays were obtained from newborn Sprague
Dawley rat pups (postnatal days 1–3) as previously de-
scribed [24].
Chemokine measurements in mouse cortical homogenates
Supernatants from the mouse cortical homogenates (see
above) were thawed, vortexed, and measured for total pro-
tein (Pierce™ Coomassie assay, ThermoFisher Scientific,
Waltham, MA, USA). The chemokines CCL-2, CCL-5,
CXCL-1, CXCL-2, CXCL-9, and CXCL-10 were measured
in by Luminex xMAP®-based assays according to the man-
ufacturer’s instructions (Merck Millipore, Darmstadt,
Germany). The cortical chemokine concentrations were
calculated based on the standard curves generated, and
expressed in pg/mg total brain protein.
Cell viability assays
The rat primary astrocytes were plated onto 24-well tissue
culture plates at a density of 1 × 105 cells per well and
treated with various concentrations of andrographolide
(0–100 μM) or LPS (0–1000 ng/mL) for 48 h. Cell con-
centrations and viability were determined with the Muse™
Cell Analyzer (Merck Millipore, Darmstadt, Germany) ac-
cording to the manufacturer’s instructions, and the per-
centages of viable cells were recorded.
RT-PCR
For measurements of chemokine expression, the treated
primary astrocytes were lysed in TRIzol® reagent (Thermo
Fisher Scientific, Waltham, MA, USA), then processed for
RNA isolation according to the manufacturer’s instruc-
tions (NucleoSpin® RNA kit, Macherey-Nagel, Düren,
Germany). The concentration and purity of RNA were
assessed using a NanoDrop spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, USA). Complementary
DNA (cDNA) was synthesized from RNA samples using a
high-capacity cDNA reverse transcriptase kit (Thermo
Fisher Scientific, Waltham, MA, USA), and semi-
quantitative real-time reverse transcription polymerase
chain reaction (RT-PCR) was performed using GoTaq®
qPCR Master Mix (Promega, Fitchburg, WI, USA) on
an Applied Biosystems® StepOnePlus™ Real-Time PCR
System (Thermo Fisher Scientific, Waltham, MA,
USA). The primer sequences of the genes of interest
are listed in Table 1, and results were normalized
against the geometric mean of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and β-actin. Fold-
change values of gene expression relative to control
were computed for each experimental group using the
2−ΔΔCT formula.
Table 1 RT-PCR primer sequences used in this study
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Immunoblotting
Treated primary astrocytes were lysed in situ by adding
a boiling Laemmli sample buffer (Bio-Rad, Berkeley, CA,
USA) onto the tissue culture plates, and resultant lysates
were further heated at 95 °C for 5 min. The samples
were electrophoretically separated on 10 % polyacryl-
amide gels, transferred onto nitrocellulose membranes
(Thermo Fisher Scientific, Waltham, MA, USA), and
blocked with 5 % non-fat milk in 10 mM phosphate-
buffered saline, pH 7.4 with 0.1 % Tween® 20 (PBST) at
room temperature for 1 h. The membranes were then
washed and probed with primary antibody diluted in
PBST with 5 % bovine serum albumin overnight at 4 °C.
The primary antibodies used were rabbit monoclonal
phospho-p65 (pSer536, clone 93H1), p65 (clone D14E12),
phospho-JNK (pThr183/pTyr185, clone 81E11), and rabbit
polyclonal JNK, all at 1:1000 dilution (Cell Signaling
Technology, Danvers, MA, USA). After primary anti-
body incubation, the membranes were washed with PBST,
then incubated with respective horse radish peroxidase
conjugated secondary antibodies (goat anti-rabbit, 1:5000;
Jackson ImmunoResearch, West Grove, PA, USA) for 1 h
at room temperature. The membranes were first probed
for phospho-proteins then stripped and re-blotted for
total proteins. Immunoblots were visualized using a
horseradish peroxidase (HRP) substrate (Luminata™
Forte or Crescendo, Merck Millipore, Darmstadt,
Germany) and quantified by an image analyzer (UVItec
Ltd., Cambridge, UK).
Statistical analyses
The results were reported as mean ± SEM, with N values
representing individual animals or independent cell-
based assays listed in the respective figure legends, and
the data analyses were performed using SPSS Statistics
software (version 21, IBM Inc., USA). Dose effects of
andrographolide and LPS were compared to the un-
treated controls using analysis of variance (ANOVA)
with Dunnett’s post hoc tests, while other pair-wise com-
parisons of the experimental groups were performed
using ANOVA followed by Bonferroni’s post hoc tests,
with p values <0.05 considered statistically significant.
Results
Effects of oral andrographolide on peripheral LPS-induced
chemokines in the cortex
To assess potential therapeutic effects of andrographolide
on neuroinflammatory conditions, a peripheral LPS ad-
ministration model was selected as it rapidly induces brain
inflammatory responses and may be pathophysiologically
more relevant to bacterial meningitis or encephalitis-
associated neuroinflammation, whose infectious source
often invade the brain parenchyma from the periphery
[33–35]. Similarly, we focused our studies on the cortex as
it is considered most disease-relevant for neuroinflamma-
tory conditions such as encephalitis. As shown in Fig. 1c,
the mice subjected to three intraperitoneal injections of
LPS over 24 h had significantly increased cortical levels of
C-C (CCL-2, CCL-5) and C-X-C (CXCL-1, CXCL-2,
CXCL-9, CXCL-10) chemokines, while LPS-treated ani-
mals administered orally with andrographolide 1 h after
each LPS injection showed reductions of all measured
chemokines except for CXCL10. Furthermore, the effects
of andrographolide on LPS-induced chemokines also ap-
peared to be dose-dependent, with 50 mg/kg showing
more extensive reductions compared to 25 mg/kg in all
responsive chemokines except CXCL9 (Fig. 1c). In the
case of CCL2, CXCL1, and CXCL2, reductions only
reached statistical significance with the higher androgra-
pholide dose. Taken together, these results indicate that
oral andrographolide administered soon after peripheral
LPS is efficacious in attenuating a range of LPS-induced
chemokines in the cortex.
Effects of andrographolide on LPS-induced chemokine
up-regulation in astrocytes
Although all brain cells respond to pro-inflammatory
signals, microglia and astrocytes are known as the pri-
mary cell types mediating both the initiation and main-
tenance of neuroinflammation [6, 31]. In the in vitro
studies, we focused on the potential involvement of as-
trocytes in mediating the chemokine responses to LPS
as well as the effects of andrographolide on these re-
sponses and first investigated possible toxicity of LPS
and andrographolide doses on cultured rat primary as-
trocytes. As shown in Additional file 1: Figure S1, astro-
cyte viability was not significantly altered by treatment
with up to 100 μM andrographolide or 1000 ng/mL LPS
for 48 h (p > 0.1, ANOVA with Dunnett’s post hoc tests).
Similar to the mice cortical studies, LPS treatment in-
duced transcription of messenger RNAs (mRNAs) for
various chemokines from the C-C (CCL2, CCL5) and C-
X-C (CXCL1, CXCL5, CXCL10) subfamilies in astro-
cytes (Fig. 2). To investigate potential effects of LPS on
other chemokines, we included the C-X3-C member,
CX3CL1 (not included in the Luminex-based kits for
mice) and showed that it was also up-regulated by LPS
(Fig. 2). The observed changes in all measured chemo-
kines were attenuated dose-dependently by andrographo-
lide pre-incubation, albeit with variable efficacy (Fig. 2).
Importantly, we showed that andrographolide added 4 h
after LPS treatment still resulted in attenuation of the
LPS-induced up-regulation in all measured chemokines
except CXCL10 (see Fig. 2, “Andro (post-LPS)” bars), sug-
gesting the potential therapeutic utility of andrographolide
after acute onset of disease.
Given the well-established roles of NF-κB and JNK
in regulating the expression of multiple inflammatory
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mediators, including the chemokines under study [27,
28, 36–38], we hypothesized that the observed LPS-
induced chemokine gene up-regulation are dependent
on NF-κB and JNK activation. Figure 3 shows that
pre-incubation with a NF-κB (TPCK [39]) or JNK
(SP600125 [40]) inhibitor was indeed able, with vari-
able efficacy, to attenuate LPS-induced up-regulation
of representative members of the C-C (CCL2), C-X-C
(CXCL1) and C-X3-C (CX3CL1) chemokines.
Effects of andrographolide on LPS-induced TNF-α up-
regulation in astrocytes
While the binding of LPS to toll-like receptor 4 rapidly
activates NF-κB which in turn induces cytokine and che-
mokine expression [36], LPS is also known to stimulate
the release of TNF-α [41–43], an acute phase protein
that is rapidly elevated in response to injury or infection
[44, 45]. In Fig. 4, we show that LPS-induced up-
regulation of TNF-α mRNA could be attenuated by
andrographolide, as well as by TPCK or SP600125, again
suggesting that in astrocytes, andrographolide’s attenua-
tive action on LPS-induced TNF-α up-regulation may be
mediated in part by the inhibition of NF-κB and JNK.
Effects of LPS and andrographolide on NF-κB and JNK
activation in astrocytes
Finally, to validate andrographolide’s effects on NF-κB
and JNK-mediated signaling which have been postulated
to underlie the regulation of TNF-α and chemokines, we
studied the effects of andrographolide on the activation
Fig. 2 Andrographolide attenuated LPS-induced chemokine mRNA up-regulation in astrocytes. Various concentrations of andrographolide (in μM)
were added to rat primary astrocytes in culture media 4 h before (“pre-LPS”) or 4 h after LPS (100 ng/mL) stimulation (“post-LPS"), then incubated
for different periods such that the total incubation time with LPS was 12 h for both “pre-LPS” and “post-LPS” groups, before processing for RT-PCR. Bar
graphs are mean ± SEM transcript fold-changes, with control levels set at 1 for N = 3 independent assays. All raw transcript values have been
normalized to mean expression of housekeeping genes (see Methods) prior to conversion to fold-change values. *p < 0.05; **p < 0.01; ***p < 0.001. n.s.
not significant (p > 0.05) for multiple pair-wise comparisons (one-way ANOVA with Bonferroni’s post hoc tests)
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of NF-κB and JNK, indicated, respectively, by p65 phos-
phorylated at Ser536 (phospho-p65) and JNK phosphory-
lated at Thr183/Tyr185 (phospho-JNK). Figure 5a showed
that in the absence of LPS, andrographolide dose-
dependently reduced phospho-p65 to below basal
levels, while having no significant effect on basal
phospho-JNK. In contrast, LPS (100 ng/mL) increased
both phospho-p65 and phospho-JNK, effects which
were dose-dependently attenuated by pre-incubation
with andrographolide (Fig. 5b). Furthermore, neither
LPS nor andrographolide appeared to affect total p65
and JNK immunoreactivities (Figs. 5a and b, bottom
representative immunoblots), suggesting both LPS and
andrographolide affect NF-κB- and JNK-mediated
pathways via phosphorylation-dependent activation or
inactivation rather than changes in NF-κB or JNK pro-
tein expression over the time-course under study.
These data, taken together with our earlier observations
of attenuation of LPS-induced TNF-α and various chemo-
kines (Figs. 3 and 4), suggest that andrographolide’s at-
tenuation of LPS-induced chemokine up-regulation in
astrocytes may be mediated, at least in part, by inhibition
of NF-κB and JNK activation.
Discussion
Chemokines are important mediators of neuroinflamma-
tory processes, and dysregulation of chemokines is impli-
cated in several diseases, thus making chemokines a viable
target in anti-inflammation therapies [46]. To this end, we
have confirmed the efficacy of oral andrographolide in
Fig. 3 Inhibitors of NF-κB or JNK attenuated LPS-induced chemokine mRNA up-regulation in astrocytes. Various concentrations of TPCK (NF-κB
inhibitor, left panels) or SP600125 (JNK inhibitor, right panels) were added to rat primary astrocytes in culture media 1 h before LPS stimulation
(100 ng/mL), then incubated for a further 12 h before processing for RT-PCR. Bar graphs are mean ± SEM transcript fold-changes, with control
levels set at 1 for N = 3 independent assays. All raw transcript values have been normalized to mean expression of housekeeping genes (see Methods)
prior to conversion to fold-change values. *p < 0.05; **p < 0.01; ***p < 0.001. n.s. not significant (p > 0.05) for multiple pair-wise comparisons (one-way
ANOVA with Bonferroni’s post hoc tests)
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Fig. 5 Andrographolide attenuated LPS-induced activation of NF-κB p65 and JNK in astrocytes. a Effects of andrographolide on basal activation of
NF-κB and JNK (indicated by immunoreactivities of phospho-p65 and phospho-JNK, respectively, see representative blots). Primary astrocytes were
treated for 6 h with various concentrations of andrographolide. b Effects of andrographolide on LPS activation of NF-κB and JNK (see representative
blots). Primary astrocytes were pretreated with various concentrations of andrographolide for 4 h followed by 1-h LPS stimulation (100 ng/mL)
in culture media. All bar graphs show immunoreactivities (mean ± SEM fold-changes in optical densities, OD, with untreated group set at 1) of
phosphorylated proteins normalized to respective total proteins, N = 3–4 independent assays. §p < 0.001, significantly different from untreated
controls (one-way ANOVA with Dunnett’s post hoc tests); **p< 0.01; ***p< 0.001. n.s. not significant (p> 0.05) for multiple pair-wise comparisons (one-way
ANOVA with Bonferroni’s post hoc tests)
Fig. 4 Andrographolide as well as inhibitors of NF-κB or JNK attenuated LPS-induced TNF-α mRNA up-regulation in astrocytes. Various concentrations
of andrographolide, TPCK, and SP600125 were added to rat primary astrocytes with LPS stimulation as described in the figure legends of Figs. 2 and 3,
before the treated cells were processed for RT-PCR. Bar graphs are mean ± SEM transcript fold-changes, with control levels set at 1 for N = 3
independent assays. All raw transcript values have been normalized to mean expression of housekeeping genes (see Methods) prior to conversion to
fold-change values. *p < 0.05; **p< 0.01; ***p < 0.001. n.s. not significant (p> 0.05) for multiple pair-wise comparisons (one-way ANOVA with Bonferroni’s
post hoc tests)
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regulating cortical chemokines from the C-C and C-X-C
subfamilies in a peripherally administered LPS model. In
separate experiments, we showed that andrographolide
also attenuated LPS-induced gene up-regulation of a
range of chemokines in cultured primary astrocytes. How-
ever, several differences exist in the two series of experi-
ments, which may be due in part to the different species
used (mice brain versus rat astrocytes), measurements of
proteins versus mRNA, and variable levels and responses
of chemokines. The selection of different species for the
different experiments was due to logistical considerations,
with mice being more easily manipulated and cost-
effective for the animal studies, while rats, due to their lar-
ger brains, allowed higher cell yield in cell culture-based
assays. Despite these limitations, our data, when consid-
ered in toto, suggest that oral andrographolide may have
utility as an anti-neuroinflammatory, and that part of its
mechanism of action may involve the regulation of
astrocyte-derived chemokines. Additionally, our findings
corroborate previous pharmacokinetic studies showing
the ability of peripheral andrographolide to cross the
blood-brain barrier (BBB) and reach the brain [47], espe-
cially during active neuroinflammation when BBB perme-
ability is altered by cytokines and chemokines from the
blood, brain, or brain endothelial cells [48, 49]. Further
considerations of andrographolide’s therapeutic utility in-
clude its low toxicity, with LD50 by oral gavage of
>4000 mg/kg/day [50]. Since our results indicated efficacy
in regulating cortical chemokines at 150 mg/kg/day (three
oral gavages of 50 mg/kg over 24 h), andrographolide will
likely have a wide therapeutic window.
Given the efficacy of andrographolide in regulating a
range of chemokines from the C-C, C-X-C, and C-X3-C
(measured only in the in vitro assays) subfamilies, it is
likely that andrographolide may influence a number of
processes mediated by these chemokines. For example,
CCL2 and CCL5 are potent chemoattractants for various
leukocytes including granulocytes, monocytes, T lym-
phocytes, natural killer cells, and dendritic cells [51]. In
experimental bacterial meningitis, CCL2 and CCL5 were
found to be significantly elevated in cerebrospinal fluid
(CSF), together with leukocyte infiltration [52], and anti-
bodies neutralizing CCL2/CCL3 have been shown to
mitigate neutrophil and macrophage recruitment into
the brain [53], suggesting potential therapeutic efficacy
for the chemokine-regulating andrographolide in bacter-
ial meningitis. For C-X-C chemokines, besides the pos-
sible involvement of CXCL1, CXCL2, and CXCL5 in
promoting leukocyte transmigration during bacterial
meningitis [52, 54], CXCL1 and CXCL2 are known to be
rapidly secreted by astrocytes in spinal cord injury, and
attenuating these chemokines was associated with re-
duced neuronal death and improved motor function re-
covery [55, 56]. Detrimental effects of CXCL5 have also
been reported in ischemic stroke, where CXCL5 eleva-
tion in CSF was associated with brain infarct size [57].
Similarly, although CXCL9 and CXCL10 expression are
vital to the host’s response to CNS viral infections [58],
persistent increases in astrocyte secretion of CXCL10 cor-
related with increased disease severity [59], while CXCL10
neutralization improved neurological outcome [60]. Fi-
nally, the only member of C-X3-C subfamily, CX3CL1, is
recognized by CX3CR1 receptors preferentially expressed
in microglia, indicating an essential role of CX3CL-1 in
regulating microglial-mediated chronic neuroinflamma-
tion [61]. Attenuation of CX3CL1 signaling by CX3CL1 or
CX3CR1 gene knockdown both significantly reduced in-
farct size, expression of IL-1β and TNF-α, and leukocyte
infiltration in ischemic stroke models [62, 63]. In the
current study, we showed that astrocytes up-regulate
CX3CL1 expression upon LPS stimulation (Fig. 3), imply-
ing the potential for crosstalk between activated astrocytes
and microglia. There is growing evidence that this cross-
talk can lead to amplification of inflammatory responses
[31, 64]. Inhibition of induced CX3CL1 expression in as-
trocytes therefore has the potential to interfere with
astrocyte-microglia crosstalk and control dysregulated
microglial activation.
Besides chemokines, cytokines such as TNF-α are re-
leased acutely in response to injury or infection [44, 45],
and function to initiate and maintain the inflammatory
process in part by stimulating other pro-inflammatory cy-
tokines (e.g., IL-1α, IL-1β, and IL-6 [65, 66]) and chemo-
kines (e.g., CCL2, CCL3, and CXCL2 [67, 68]). Therefore,
our study suggests two pathways by which andrographo-
lide attenuate LPS-induced chemokines, a direct pathway
targeting LPS induction of chemokines and an indirect
one via LPS-induced TNF-α. Interestingly, both pathways
seem to be dependent on NF-κB and JNK activities (Figs. 3
and 4), and andrographolide’s mechanism of inhibitory ac-
tion seems to be mediated in part by inactivation of these
signaling molecules (Fig. 5). Furthermore, our data suggest
that andrographolide may act synergistically with other
potential anti-neuroinflammatory therapeutics such as se-
lective estrogen receptor modulators [69, 70].
Conclusions
In summary, we showed in a peripheral LPS-treated
mouse model and in rat primary astrocytes that androgra-
pholide has efficacy in abrogating LPS induction of che-
mokine up-regulation, in part by inactivation of NF-κB
and JNK (Fig. 6). This suggests the potential utility of
andrographolide as a therapeutic for neuroinflammatory
conditions, especially those characterized by dysregulation
of astrocyte-derived chemokines [8–11]. However,
further work is needed to (i) characterize the effects of
andrographolide in other brain cell types, e.g., neurons
and microglia; (ii) better understand the dose-response
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relationships (for e.g., would there be more significant
effects on CXCL10 (Figs. 1 and 2) with higher andro-
grapholide doses?); (iii) confirm the behavioral corre-
lates of chemokine regulation (for e.g., does
inflammation-associated sickness behavior or cognitive
impairments [34, 61] improve?); and (iv) elucidate other
molecular pathways underlying andrographolide actions
in the CNS (for e.g., involvement of mitogen-activated
protein kinase-mediated signaling pathways [71] or
with other components of signaling complexes like NF-
κB p50 subunit [72]). It is expected that these studies
will help further assess the feasibility of using androgra-
pholide as an anti-neuroinflammatory therapeutic.
Additional file
Additional file 1: Figure S1. Supplementary Fig. 1. Cell viability of
primary astrocytes (in mean ± S.E.M. % of untreated) after 48 h incubation
with andrographolide and LPS at the indicated concentrations. (ESM 210 kb)
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